Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half ...

Dermata Therapeutics shares jumped more than 50% in early trading Thursday after the biotechnology company said its Xyngari once-weekly, topical product candidate for the treatment of ...

Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today ...

Shares of Dermata Therapeutics, Inc. (Nasdaq: DRMA) climbed 60% following the announcement of successful Phase 3 trial results for their acne treatment, XYNGARI, ...

The fifth product, Seysara (sarecycline) an oral acne treatment, is awaiting approval – likely by the end of the year – by the US Food and Drugs Administration (FDA) following the positive ...

They’re a seriously qualified and experienced group and have undertaken specific research to create individual treatments for acne, fine lines and wrinkles, pigmentation and melasma. The ...

Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical ...